tiprankstipranks
Trending News
More News >
Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
Advertisement

Autolus Therapeutics (AUTL) AI Stock Analysis

Compare
684 Followers

Top Page

AU

Autolus Therapeutics

(NASDAQ:AUTL)

Rating:54Neutral
Price Target:
$2.50
▼(-4.21%Downside)
The overall score reflects significant upward momentum in technical analysis, offset by financial challenges due to ongoing losses and cash flow issues. The positive earnings call outlook is tempered by valuation concerns given the negative P/E ratio.
Positive Factors
Market Expansion
Strong growth in 2025 is expected as the company aims to expand to 60 target centers, covering about 90% of the target population.
Product Efficacy
Strong efficacy/safety data demonstrated in the pivotal FELIX study contributed to the positive regulatory decision for Aucatzyl.
Regulatory Approvals
Aucatzyl received conditional EU approval in adult patients with relapsed/refractory acute lymphoblastic leukemia.
Sales Performance
Autolus reported an impressive $9.0 million in sales for Aucatzyl in the first quarter, substantially beating the estimate of $2.9 million.
Negative Factors
Market Coverage
The launch of Aucatzyl with only about 60% of the target U.S. B-ALL population covered by activated centers is considered a strong start.
Regulatory Challenges
Receiving a positive NICE opinion will be important for achieving widespread payor coverage.

Autolus Therapeutics (AUTL) vs. SPDR S&P 500 ETF (SPY)

Autolus Therapeutics Business Overview & Revenue Model

Company DescriptionAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
How the Company Makes MoneyAutolus Therapeutics primarily generates revenue through research and development collaborations, strategic partnerships, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales of any successfully commercialized therapies. The company also seeks funding through public and private offerings of equity securities to support its clinical trials and research activities. As a clinical-stage company, Autolus does not yet generate revenue from product sales, as its therapies are still under development and regulatory approval processes.

Autolus Therapeutics Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q1-2025)
|
% Change Since: 112.20%|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment Neutral
The earnings call presented a strong start for AUCATZYL with significant interest and revenue generation. Geographic expansion and promising data in autoimmune diseases further bolstered positive outlooks. However, high costs and increased net loss present financial challenges that need addressing.
Q1-2025 Updates
Positive Updates
Strong Launch of AUCATZYL
Autolus reported $9 million in recognized revenue in the first quarter from the launch of AUCATZYL. The product has been well-received, with 39 centers authorized to deliver it and approximately 90% of total U.S. medical lives covered.
Geographic Expansion
Autolus received conditional marketing authorization from the MHRA in the UK and is engaging with NICE for reimbursement. Progression in Europe is ongoing, with an expected decision from the European agency in the second half of the year.
Positive Developments in Autoimmune Disease
Phase 1 CARLYSLE study in Systemic Lupus Erythematosus showed promising results, with patients achieving renal complete remissions and no neurological toxicities observed.
Financial Stability
Autolus ended Q1 2025 with $516.6 million in cash, cash equivalents, and marketable securities, providing a strong foundation for ongoing and future projects.
Negative Updates
High Cost of Sales
The cost of sales for Q1 2025 was $18 million, which exceeds the revenue generated, indicating a need for cost management improvements.
Increased Net Loss
Net loss for Q1 2025 was $70.2 million, compared to $52.7 million for the same period in 2024, highlighting financial challenges despite revenue growth.
Deferred Revenue Impact
About $4.7 million in deferred revenue was noted, indicating potential delays in revenue recognition due to product delivery and administration timing.
Company Guidance
During the Autolus First Quarter 2025 Financial Results Conference Call, guidance was provided on several key metrics. The company reported $9 million in recognized revenue for Q1 2025, marking a strong start for AUCATZYL's U.S. launch. Additionally, they have authorized 39 clinical centers to deliver AUCATZYL, covering about 90% of total U.S. medical lives. The Centers for Medicare & Medicaid Services (CMS) published reimbursement codes for AUCATZYL on April 1, facilitating its eligibility for reimbursement under government programs. Looking ahead, Autolus plans to increase the number of centers to approximately 60 by year-end, aiming for broad patient access. They also highlighted the potential geographic expansion into the UK, having received conditional marketing authorization from the MHRA, and are engaging with relevant bodies for reimbursement processes. Autolus' cash position at the end of Q1 2025 was $516.6 million, down from $588 million at the end of December 2024, primarily due to operating and investing activities. The company maintains confidence in its financial foundation to support ongoing commercialization efforts and clinical trials.

Autolus Therapeutics Financial Statement Overview

Summary
Autolus Therapeutics is experiencing revenue growth but struggles with profitability and cash flow management. Despite a strong balance sheet, operational losses and negative cash flows present significant challenges.
Income Statement
25
Negative
Autolus Therapeutics has shown significant revenue growth in recent years, with a notable increase from $1.7M in 2023 to $10.1M in 2024. However, the company continues to report negative gross and net profit margins, indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are also negative, reflecting substantial operational losses.
Balance Sheet
40
Negative
The company's balance sheet highlights a strong equity position, with a substantial cash reserve relative to its liabilities. The debt-to-equity ratio is low at 0.12, suggesting limited leverage, but the company has consistently negative net income affecting ROE, which remains negative. The equity ratio is relatively stable, indicating a solid asset structure.
Cash Flow
30
Negative
Autolus Therapeutics is facing challenges with negative free cash flow, which has worsened in recent periods. Although operating cash flow is negative, it is supported by financing activities, indicating reliance on external funding. The free cash flow to net income ratio is unfavorable, reflecting difficulties in converting income into cash.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue10.12M1.70M6.19M2.33M242.00K
Gross Profit-1.27M-4.87M-131.03M-126.32M-134.65M
EBITDA-182.42M-156.77M-135.54M-132.01M-160.51M
Net Income-220.66M-208.38M-148.84M-142.10M-142.09M
Balance Sheet
Total Assets782.73M375.38M490.27M405.56M294.24M
Cash, Cash Equivalents and Short-Term Investments588.02M239.57M382.44M310.34M153.30M
Total Debt52.63M52.97M24.26M21.00M54.16M
Total Liabilities355.40M263.91M191.60M92.24M84.20M
Stockholders Equity427.32M111.47M298.67M313.32M210.03M
Cash Flow
Free Cash Flow-241.09M-156.57M-123.15M-126.72M-132.44M
Operating Cash Flow-206.27M-145.59M-112.31M-117.86M-117.76M
Investing Cash Flow-394.55M-10.99M-10.84M-8.86M-14.68M
Financing Cash Flow589.55M-883.00K223.61M284.06M74.42M

Autolus Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.61
Price Trends
50DMA
2.05
Positive
100DMA
1.81
Positive
200DMA
2.37
Positive
Market Momentum
MACD
0.12
Positive
RSI
66.81
Neutral
STOCH
43.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Positive. The current price of 2.61 is above the 20-day moving average (MA) of 2.40, above the 50-day MA of 2.05, and above the 200-day MA of 2.37, indicating a bullish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 66.81 is Neutral, neither overbought nor oversold. The STOCH value of 43.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AUTL.

Autolus Therapeutics Risk Analysis

Autolus Therapeutics disclosed 86 risk factors in its most recent earnings report. Autolus Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Autolus Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
$463.04M-48.98%-9.95%20.78%
54
Neutral
$641.40M-49.91%-14.16%25.88%
52
Neutral
$7.46B-0.04-63.82%2.49%16.43%<0.01%
ALALT
51
Neutral
$340.65M-57.28%-95.12%21.09%
45
Neutral
$474.72M-26.14%74.59%
44
Neutral
$535.79M-33.14%
44
Neutral
$514.60M-115.39%-4.14%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AUTL
Autolus Therapeutics
2.61
-1.68
-39.16%
ALT
Altimmune
4.20
-2.23
-34.68%
CELC
Celcuity
13.94
-4.47
-24.28%
TRML
Tourmaline Bio
18.86
3.40
21.99%
ABSI
AbSci
3.63
-0.82
-18.43%
RAPP
Rapport Therapeutics, Inc.
15.20
-5.15
-25.31%

Autolus Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
Autolus Therapeutics Passes All AGM Resolutions
Neutral
Jun 27, 2025

On June 26, 2025, Autolus Therapeutics held its Annual General Meeting where all nine proposed resolutions were passed. Key resolutions included the adoption of the 2024 Annual Report, approval of the Directors’ remuneration report and policy, re-appointment of Ernst & Young LLP as auditors, re-election of Dr. R Iannone and Dr. R Rao as Directors, and the approval of the Employee Share Purchase Plan.

The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Shareholder MeetingsFinancial Disclosures
Autolus Therapeutics Releases UK Annual Report 2024
Neutral
Jun 2, 2025

On June 2, 2025, Autolus Therapeutics plc released its UK Annual Report and Accounts for the year ending December 31, 2024, and announced its upcoming annual general meeting scheduled for June 26, 2025. Citibank, as the depositary bank for Autolus’s American Depositary Shares, began distributing voting materials to ADS holders, allowing them to instruct the bank on voting their shares, although there may be limitations affecting timely voting.

The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Autolus Therapeutics Directors Announce Departure Plans
Neutral
May 30, 2025

On May 23, 2025, Drs. Joseph Anderson and Martin Murphy announced their decision not to seek re-election to the Board of Directors of Autolus Therapeutics at the upcoming Annual General Meeting. Their resignation is not due to any disagreements with the company’s management or board, suggesting a smooth transition and stability within the company’s governance structure.

The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Autolus Therapeutics Reports Q1 2025 Financial Results
Neutral
May 8, 2025

Autolus Therapeutics reported its financial results for the first quarter of 2025, highlighting a net product revenue of $9.0 million from AUCATZYL® and securing marketing authorization from the U.K.’s MHRA. The company is advancing its clinical trials, including a Phase 2 trial for lupus nephritis and a Phase 1 trial for multiple sclerosis, with plans to dose the first patients by the end of 2025. Despite a net loss of $70.2 million for the quarter, Autolus remains well-capitalized to support its ongoing and planned clinical developments, aiming to expand its therapeutic reach and address significant unmet medical needs.

Business Operations and Strategy
Autolus Therapeutics to Present R&D Update April 23
Neutral
Apr 23, 2025

On April 23, 2025, Autolus Therapeutics will present a corporate update at an R&D investor event, which will be accessible via a live webcast and archived on the company’s website. This presentation may impact the company’s operations and industry positioning by providing stakeholders with insights into its ongoing research and development efforts.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 15, 2025